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Abstract
Background: Suitable algorithms based on a combination of two or more simple rapid HIV assays have
been shown to have a diagnostic accuracy comparable to double enzyme-linked immunosorbent assay
(ELISA) or double ELISA with Western Blot strategies. The aims of this study were to evaluate the
performance of five simple rapid HIV assays using whole blood samples from HIV-infected patients,
pregnant women, voluntary counseling and testing attendees and blood donors, and to formulate an
alternative confirmatory strategy based on rapid HIV testing algorithms suitable for use in Tanzania.
Methods: Five rapid HIV assays: Determine™ HIV-1/2 (Inverness Medical), SD Bioline HIV 1/2 3.0
(Standard Diagnostics Inc.), First Response HIV Card 1–2.0 (PMC Medical India Pvt Ltd), HIV1/2 Stat-Pak
Dipstick (Chembio Diagnostic System, Inc) and Uni-Gold™ HIV-1/2 (Trinity Biotech) were evaluated
between June and September 2006 using 1433 whole blood samples from hospital patients, pregnant
women, voluntary counseling and testing attendees and blood donors. All samples that were reactive on
all or any of the five rapid assays and 10% of non-reactive samples were tested on a confirmatory Inno-Lia
HIV I/II immunoblot assay (Immunogenetics).
Results: Three hundred and ninety samples were confirmed HIV-1 antibody positive, while 1043 were
HIV negative. The sensitivity at initial testing of Determine, SD Bioline and Uni-Gold™ was 100% (95% CI;
99.1–100) while First Response and Stat-Pak had sensitivity of 99.5% (95% CI; 98.2–99.9) and 97.7% (95%
CI; 95.7–98.9), respectively, which increased to 100% (95% CI; 99.1–100) on repeat testing. The initial
specificity of the Uni-Gold™ assay was 100% (95% CI; 99.6–100) while specificities were 99.6% (95% CI;
99–99.9), 99.4% (95% CI; 98.8–99.7), 99.6% (95% CI; 99–99.9) and 99.8% (95% CI; 99.3–99.9) for
Determine, SD Bioline, First Response and Stat-Pak assays, respectively. There was no any sample which
was concordantly false positive in Uni-Gold™, Determine and SD Bioline assays.
Conclusion: An alternative confirmatory HIV testing strategy based on initial testing on either SD Bioline
or Determine assays followed by testing of reactive samples on the Determine or SD Bioline gave 100%
sensitivity (95% CI; 99.1–100) and 100% specificity (95% CI; 96–99.1) with Uni-Gold™ as tiebreaker for
discordant results.
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Background
Several types of assays for HIV antibody detection have
been developed and promoted for HIV screening and
diagnosis. Enzyme-linked immunosorbent assay (ELISA)
is the most commonly used technique for screening pur-
poses followed by confirmatory testing, most commonly
by using Western blot (WB) assay or a second ELISA based
on a different test principle and antigen source in an alter-
native confirmatory strategy. Simple rapid HIV assays
which do not require use of instruments have been widely
used especially in resource limited settings including Afri-
can countries. Currently there are many different commer-
cially available ELISAs, as well as simple rapid HIV assays
for detection of antibodies to HIV. Evaluation of various
anti-HIV-1 assays using panels of American and European
sera have shown that most of these assays have a high sen-
sitivity and specificity [1]. However, studies have shown
that some of these assays do not have a similar test per-
formance when used for testing of African sera [2]. It is
therefore generally recommended to evaluate HIV assays
in the context in which they will be used before adopting
them for wide scale use [3,4].
Various combinations of ELISAs as alternative confirma-
tory strategies have been shown to have the same diagnos-
tic accuracy as the use of antibody ELISA followed by WB
assay [5]. In recent years, interest has centred on the use of
simple rapid HIV assays, especially in voluntary counsel-
ling and testing (VCT) facilities. Suitable algorithms based
on a combination of two or more simple rapid assays have
been shown to have diagnostic accuracy comparable to
double ELISA or double ELISA and WB testing strategies
[6-9]. Current initiatives and interventions for prevention
of mother-to-child transmission (PMTCT) of HIV-1
require the use of simple rapid assays in VCT services and
antenatal clinics aiming at giving same day results. The
World Health Organization (WHO) performance charac-
terization of rapid HIV tests shows that a number of assays
perform very well using international panels of blood
samples. Likewise, new assays entering the diagnostics
market address both performance characteristics and
operational requirements that allow expansion of access
to HIV testing in resource-constrained countries.
The current rapid HIV testing algorithm which is in use in
Tanzania was developed 6 years ago [10]. This serial test-
ing algorithm is based on the use of Capillus HIV-1/2
assay (Trinity Biotech, Ireland) for screening followed by
confirmatory testing of reactive samples by Determine™
HIV-1/2 assay (Abbott Diagnostics, UK) [10]. Capillus
assay requires cold storage, making it unsuitable for use in
hard to reach areas where electricity is not available or in
settings where power outages are frequent. The cold chain
dependency for Capillus assay coupled with availability
on the market, of newer HIV rapid tests that are cheaper,
do not require cold storage and have acceptable perform-
ance characteristics compelled the Ministry of Health and
Social Welfare to embark on evaluation of some of these
rapid HIV assays aiming at developing alternative algo-
rithms for use in Tanzania. Furthermore, there is an urgent
need within the country for a suitable algorithm(s) that
meet the demand for the scale up of access to HIV screen-
ing, diagnosis, treatment and care in line with the Ministry
of Health and Social Welfare Strategic Plan for Prevention,
Treatment and Care for HIV/AIDS.
The aims of this study were to evaluate the performance of
five simple rapid HIV assays using whole blood samples
from hospital patients, pregnant women, VCT attendees
and blood donors, and to formulate an alternative cost-
beneficial confirmatory strategy based on rapid HIV test-
ing algorithms suitable for use in Tanzania.
Methods
Selection of Rapid HIV Assays for Evaluation
The rapid HIV assays which were included in the evalua-
tion were selected according to the following WHO rec-
ommended criteria: cost per test (< 2 US$), sensitivity
(100%), specificity (≥ 99%), additional requirements for
items not provided in the kit, experience of use of the kit
in the African region, test kit registered in the country,
sample type requirements (whole blood, plasma or
serum), shelf life (9 months and above), experience of use
of the kit in the country and kit storage requirements (2–
30°C). Eighteen rapid HIV assays were subjected to the
selection criteria. The selection was made by an Evalua-
tion Technical Committee and approved by a Rapid Test
Kit (RTK) Evaluation Management Committee appointed
by the Ministry of Health and Social Welfare. Five simple
rapid HIV assays that included Determine™ HIV-1/2
(Inverness Medical Japan Co. Ltd, Japan), SD Bioline HIV
1/2 3.0 (Standard Diagnostics Inc., Kyonggi-do, Korea),
First Response HIV Card 1–2.0 (PMC Medical India Pvt
Ltd, Daman, India), HIV1/2 Stat-Pak Dipstick (Chembio
Diagnostic System, Inc., New York, USA) and Uni-Gold™
HIV-1/2 (Trinity Biotech, Wicklow, Ireland) were selected
for evaluation. These are qualitative assays for the detec-
tion of antibodies (IgG, IgM, IgA) specific to HIV-1 and
HIV-2 simultaneously in human serum, plasma or whole
blood.
Collection of blood samples
Whole blood samples were collected consecutively within
the City of Dar es Salaam from the Pastoral AIDS services
of the Archdiocese of Dar es Salaam (PASADA) Care and
Treatment Clinic, the African Medical Research Founda-
tion (AMREF) and Muhimbili Health Information Centre
(MHIC) VCT clinics and from the Muhimbili National
Hospital (MNH) PMTCT clinic and Blood Bank. PASADA
and MHIC are health facility/hospital based VCT sites andBMC Infectious Diseases 2009, 9:19 http://www.biomedcentral.com/1471-2334/9/19
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therefore have been clustered into one category; MNH
blood bank represents a setting for HIV screening for
blood; MNH PMTCT is a site for screening pregnant
women and AMREF is a typical stand-alone VCT. At each
site the left over blood specimens from routine testing
were collected without patient/client identifiers and were
used for the evaluation. At the end of the clinic day, the
unlabeled blood specimens were collected from the indi-
vidual sites by the designated laboratory technologist
from the National HIV Reference Laboratory (NHRL) in
the Department of Microbiology and Immunology,
Muhimbili University of Health and Allied Sciences
(MUHAS) who signed a register and dispatch book to
ensure accountability of specimens. All specimens col-
lected every day were recorded in the first register book
(which included the date and time of specimen collection,
serial number, initials of site of collection and pick up per-
sonnel) using assigned serial numbers. Following receipt
at the NHRL, every specimen was logged in the second
register book (which included the date and time of speci-
men delivery, laboratory ID number, initials of the receiv-
ing and testing personnel) and were assigned a laboratory
identification number before being given to designated
laboratory technologists for testing. A total of 1649 whole
blood samples were collected between June and Septem-
ber 2006: 324 from patients attending PASADA clinic,
121 from pregnant women attending MNH PMTCT, 602
and 311 from AMREF and MHIC VCT clinics, respectively,
and 291 from blood donors. The HIV serostatus of sam-
ples used was unknown prior the evaluation.
Rapid HIV testing
A trained laboratory technologist performed one type of
rapid HIV assay on all blood samples submitted for eval-
uation each day. Each blood sample was tested using the
listed rapid HIV assay in the NHRL, Department of Micro-
biology and Immunology, MUHAS. Testing on each assay
was performed using whole blood according to manufac-
turer's instructions of individual test kits. HIV results of
individual samples were recorded after reading by two dif-
ferent laboratory technologists according to manufac-
turer's criteria for interpretation of positive, negative or
inconclusive results. Repeat testing was done on any sam-
ple that gave invalid/equivocal result according to manu-
facturer's interpretation of results. All results were checked
by the testing laboratory technologists and subsequently
verified by a clinical microbiologist. Every testing labora-
tory technologist independently submitted the rapid HIV
results on daily basis to a designated senior lab technolo-
gist who compared with results from the other four assays
under evaluation and would inform the testing technolo-
gist to do repeat testing if any result was discordant.
Repeat testing results were also recorded. Inno-Lia HIV I/
II immunoblot assay (Immunogenetics) was used as a ref-
erence method. All samples that were reactive on all or
any of the five HIV rapid assays and 10% of non-reactive
samples randomly selected were confirmed on the Inno-
Lia HIV I/II assay. A total of 1649 samples were tested
from different sites and 199 samples tested in the first two
days of evaluation were considered as pilot samples.
These included 29 samples from PASADA, 81 from
AMREF, 35 from MHIC, 23 from MNH PMTCT and 31
from MNH Blood bank. Data on performance appraisal
done by testing laboratory technologists based on the fol-
lowing characteristics in the check list: number of steps in
the test procedure, clarity of kit instructions, kit and rea-
gent packaging and labeling, and ease of performance, as
used in the previous study, [10] were also obtained.
Criteria for inclusion into the National Algorithm
The criteria for inclusion of an individual rapid HIV assay
into the National algorithm were initial sensitivity of
100% and initial specificity of ≥ 99%.
Ethical consideration
The study was carried out in line with existing ethical
guidelines. Ethical clearance was obtained from the
Muhimbili University of Health and Allied Sciences
Research and Publications Committee. Permission to con-
duct this evaluation was given by the Ministry of Health
and Social Welfare, Tanzania. Samples were only identi-
fied by assigned identification numbers and were not
linked to client identifiers, and thus ensuring confidenti-
ality.
Statistical analyses
One hundred and ninety nine pilot samples and those
that gave inconclusive and/or western blot indeterminate
(17) test results were excluded. Epi Info™ program version
6.7 was used for analysis. Sensitivity and specificity with
95% confidence intervals (CI) of individual rapid HIV
assay and combinations of various assays were deter-
mined. Positive predictive value (PPV) and negative pre-
dictive value (NPV) (with 95% CI) were also determined.
Results
Of a total of 1433 samples that were tested and included
in the final analysis, 390 were confirmed HIV-1 antibody
positive by the Inno-Lia and 1043 were HIV negative. The
sensitivity and specificity of the five evaluated assays are
presented in Table 1. On initial testing, Determine, SD
Bioline and Uni-Gold™ each had sensitivity of 100%
(95% CI; 99.1–100) while the initial specificity of the
Uni-Gold™ assay was 100% (95% CI; 99.6–100). Of the
five assays evaluated, HIV 1/2 Stat-Pack Dipstick had com-
paratively lowest sensitivity and specificity parameters on
initial testing. However, after repeat testing performance
increased to 100% for both sensitivity and specificity. The
performance of First Response was also comparatively low
on initial testing, and only sensitivity increased to 100%BMC Infectious Diseases 2009, 9:19 http://www.biomedcentral.com/1471-2334/9/19
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on repeat testing. There was no any sample which was
concordantly false positive in the above three assays.
The sensitivity and specificity of the assays using whole
blood samples from various sites are shown in Table 2.
Uni-Gold™ had the best performance characteristics with
100% sensitivity and 100% specificity on samples from
any of the sites. The Determine, SD Bioline and Uni-
Gold™ rapid HIV assays had sensitivity of 100% on sam-
ples from each of these sites. All assays had sensitivity of
100% and specificity of 100% on samples from the ante-
natal clinic at MNH. None of the 10% nonreactive sam-
ples randomly selected were positive in the Inno-lia
confirmatory antibody assay.
The positive predictive values (PPV) were 99% (95% CI;
97.4–99.7%) for the Determine, 98.5% (95% CI; 96.7–
99.4%) for SD Bioline HIV-1/2 3.0, 100% (95% CI; 99.1–
100%) for Uni-Gold™, 98.5% (95% CI; 96.7–99.4%) for
First Response and 97.2% (95% CI; 95–98.6%) for Stat-
Pak Dipstick assays. The negative predictive value (NPV)
at initial testing was 100% (95% CI; 99.6–100%) except
First Response (99.8%, 95% CI; 99.3–99.9%) and Stat-
Pak Dipstick (99.1%, 95% CI; 98.4–99.6%) assays.
Sensitivity, specificity and cost of each of the various com-
binations of the rapid HIV assays evaluated in an alterna-
tive confirmatory testing strategy are shown in Table 3.
Several combinations of HIV rapid assays showed sensi-
tivity and specificity of 100%. The cost of an algorithm is
based on the cost of screening a sample on the first rapid
HIV assay and confirmation of a reactive sample on the
second rapid HIV assay.
Performance appraisal of HIV rapid assays by testing lab-
oratory technologists revealed that SD Bioline, Deter-
mine, Uni-Gold™ and First Response assays had similar
high score while Stat-Pak had a low score. Ease of per-
Table 1: Summary of Sensitivity and Specificity of the Rapid HIV Assays Evaluated
Assay Sensitivity (n = 390) Specificity (n = 1043)
Initial testing Repeat testing Initial testing Repeat testing
Reactive % (95% CI) Reactive % (95% CI) Non-reactive % (95% CI) Non-reactive % (95% CI)
Determine 390 100 (99.1–100) - - 1039 99.6 (99–99.9) 1041 99.8 (99.3–100)
SD Bioline 390 100 (99.1–100) - - 1037 99.4 
(98.8–99.7)
1041 99.8 
(99.3–99.9)
Uni-Gold™ 390 100 (99.1–100) - - 1043 100 (99.6–100) - -
First Response 388 99.5 
(98.2–99.9)
390 100 (99.1–100) 1039 99.6 (99–99.9) 1040 99.7 
(99.2–99.9)
Stat-Pak 
Dipstick
381 97.7 
(95.7–98.9)
390 100 (99.1–100) 1041 99.8 
(99.3–99.9)
1043 100 (99.6–100)
CI, confidence interval
Table 2: Performance characteristics of HIV rapid tests according to the samples collected from the sites
Assay Site
PASADA + MHIC MNH Blood bank MNH PMTCT AMREF
Sensitivity
n (%) 95%CI
Specificity
n (%) 95%CI
Sensitivity
n (%) 95%CI
Specificity
n (%) 95%CI
Sensitivity
n (%) 95%CI
Specificity
n (%) 95%CI
Sensitivity
n (%) 95%CI
Specificity
n (%) 95%CI
Determine 322/322 (100) 
98.9–100
239/241 
(99.2)
97.0–99.9
12/12 (100)
73.5–100
246/247 (99.6)
97.8–100
19/19 (100)
82.4–100
82/82 (100)
95.6–100
37/37 (100)
90.5–100
472/473 
(99.8)
98.8–100
SD Bioline 322/322 (100)
98.9–100
237/2471
(100)
95.8–99.6
12/12 (100)
73.5–100
245/247 (99.2)
97.1–99.9
19/19 (100)
82.4–100
82/82
(100)
95.6–100
37/37 (100)
90.5–100
473/473 (100)
99.2–100
Uni-Gold™ 322/322 (100) 
98.9–100
241/241 (100)
98.5–100
12/12 (100)
73.5–100
247/247 (100)
98.5–100
19/19 (100)
82.4–100
82/82 (100)
95.6–100
37/37 (100)
90.5–100
473/473 (100)
99.2–100
First 
Response
321/322 (99.7)
98.3–100
238/241 
(98.8)
96.4–99.7
11/12
(91.7)
61.5–99.8
246/247 (99.6)
97.8–100
19/19
(100)
82.4–100
82/82 (100)
95.6–100
37/37 (100)
90.5–100
473/473 (100)
99.2–100
Stat-Pak 
Dipstick
316/322 (98.1)
96–99.3
238/241 
(98.8)
96.4–99.7
12/12 (100)
73.5–100
247/247 (100) 
98.5–100
19/19 (100)
82.4–100
82/82 (100)
95.6–100
34/37 (91.9)
78.1–98.3
472/473 
(98.8)
98.8–100BMC Infectious Diseases 2009, 9:19 http://www.biomedcentral.com/1471-2334/9/19
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formance for SD Bioline assay was reported by testing lab-
oratory technologists to be very easy compared to the
other four assays evaluated.
Discussion
This evaluation was based on the testing of whole blood
samples on the five selected rapid HIV assays. Determine,
SD Bioline and Uni-Gold™assays had initial sensitivity of
100% (95% CI; 99.1–100) while the initial specificity of
the Uni-Gold™ assay was 100% (95% CI; 99.6–100).
Overall the performance characteristics of First Response
and HIV 1/2 Stat-Pak assays were lower compared to those
of Determine, SD Bioline and Uni-Gold™ assays.
The findings of sensitivity of 100% and specificity of
99.4% for SD Bioline in the present evaluation are in
agreement with results reported elsewhere [12]. The find-
ings of 100% sensitivity for Determine and Uni-Gold™
assays found in this evaluation were consistent with find-
ings documented in other studies [10,13,14]. The 100%
specificity for Uni-Gold™ assay is in contrast with findings
from other studies [13,14]. In a previous study that was
conducted in Uganda [14], blood donor samples from
low HIV prevalence population were used [14] compared
to blood samples from different groups including high
prevalence population such as hospital patients and preg-
nant women. In the present evaluation the sensitivity of
First Response was lower [(99.5%) 95% CI; 98.2–99.9]
than that reported by the manufacturer (100%) while the
specificity in the present study [(99.6%) 95% CI 99–
99.9%] was higher that that reported by the manufacturer
(99.18%). The sensitivity of 97.7% for Stat-Pak assay is
lower compared to 100% sensitivity found though the
specificity is comparable with that reported from a study
done in another setting [14]. Variations in performance of
rapid HIV assays in different settings especially with differ-
ent levels of antigenic challenge are well known. In addi-
tion, differences in the performance may relate in part to
their inability to detect low antibody titres in people tak-
ing antiretroviral therapy with low viral loads. However,
in the present study, no specific information was solicited
regarding the use of antiretroviral drugs making it difficult
to explain the lowest performance of some of the rapid
HIV assays evaluated.
Of the five rapid HIV assays evaluated, Uni-Gold™, Deter-
mine and SD Bioline were shown to have the required
sensitivity and specificity for inclusion into the National
rapid HIV testing algorithm. It is possible to have different
algorithms based on different combinations of Deter-
mine, SD Bioline and Uni-Gold™ assays. From the site
specific performance characteristics of the tests, it would
appear that a combination comprising of Uni-Gold™ as a
first test and Determine or SD Bioline as a second test
Table 3: Sensitivity (n = 390), specificity (n = 1043) and cost of various combinations of rapid HIV assays
S/N 1st Assay 2nd Assay Sensitivity % (95% CI) Specificity % (95% CI) Cost per algorithm (US$)
1 SD Bioline First Response 100 (99.1–100) 99.9** (99.5–99.9) 0.47 + 0.65 = 1.12
2 First Response*** SD Bioline 99.5 (98.2–99.9) 100 (96–99.1) 0.65 + 0.47 = 1.12
3 SD Bioline Determine 100 (99.1–100) 100* (96–99.1) 0.47 + 0.80 = 1.27
4 Determine SD Bioline 100 (99.1–100) 100* (96–99.1) 0.80 + 0.47 = 1.27
5 SD Bioline Stat-Pak Dipstick 100 (99.1–100) 100* (96–99.1) 0.47 + 0.80 = 1.27
6 Stat-Pak Dipstick*** SD Bioline 97.9 (96–99.1) 100 (96–99.1) 0.80 + 0.47 = 1.27
7 Determine First Response 100 (99.1–100) 100* (96–99.1) 0.80 + 0.65 = 1.45
8 First Response*** Determine 99.5 (98.2–99.9) 99.9 (99.5–99.9) 0.65 + 0.80 = 1.45
9 First Response*** Stat-Pak Dipstick 99.5 (98.2–99.9) 100 (96–99.1) 0.65 + 0.80 = 1.45
10 Stat-Pak Dipstick*** First Response 97.9 (96–99.1) 100 (96–99.1) 0.80 + 0.65 = 1.45
11 Determine Stat-Pak Dipstick 100 (99.1–100) 100* (96–99.1) 0.80 + 0.80 = 1.60
12 Stat-Pak Dipstick*** Determine 97.9 (96–99.1) 100 (96–99.1) 0.80 + 0.80 = 1.60
13 SD Bioline Uni-Gold™ 100 (99.1–100) 100* (96–99.1) 0.47 + 1.80 = 2.27
14 Uni-Gold™ SD Bioline 100 (99.1–100) 100* (96–99.1) 1.80 + 0.47 = 2.27
15 Uni-Gold™ First Response 100 (99.1–100) 100* (96–99.1) 1.80 + 0.65 = 2.45
16 First Response*** Uni-Gold™ 99.5 (98.2–99.9) 100 (96–99.1) 0.65 + 1.80 = 2.45
17 Uni-Gold™ Stat-Pak Dipstick 100 (99.1–100) 100* (96–99.1) 1.80 + 0.80**** = 2.6
18 Stat-Pak Dipstick*** Uni-Gold™ 97.9 (96–99.1) 100 (96–99.1) 0.80 + 1.80 = 2.60
19 Determine Uni-Gold™ 100 (99.1–100) 100* (96–99.1) 0.80 + 1.80 = 2.60
20 Uni-Gold™ Determine 100 (99.1–100) 100* (96–99.1) 1.80 + 0.80 = 2.60
*Combination of the two assays had no concordant false positive results.
**One sample was repeatedly concordantly false positive in the two assays.
***The first test had initial suboptimal sensitivity (< 100%).
****Cost of Stat-Pak Dipstick is indicated as a range 0.8–0.95 US$. The best case scenario of the lowest possible cost for this test was assumed in 
computing the cost for algorithms involving use of Stat-Pak Dipstick.BMC Infectious Diseases 2009, 9:19 http://www.biomedcentral.com/1471-2334/9/19
Page 6 of 7
(page number not for citation purposes)
would be suitable in all settings. On the other hand, a
combination comprising of SD Bioline followed by Uni-
Gold™ would possibly be useful, in a descending order of
priority in: PMTCT and stand alone VCT (equally); facil-
ity-based VCT; and blood bank. A combination compris-
ing of Determine followed by Uni-Gold™ would possibly
be useful, in a descending order of priority in: PMTCT,
stand alone VCT, blood bank and facility based VCT while
a combination involving use of SD Bioline followed by
Determine would be useful in facility-based VCT, PMTCT
setting and stand alone VCT settings. Since all assays have
sensitivity of 100%, in the event of shortage of any of the
three assays, any available assay (among the three) can be
used as the first assay. Determine is one of the assays in
the currently used algorithm while SD Bioline is licensed
for use in the country. In view of the present results show-
ing acceptable performance characteristics of these three
assays and taking into account the multiple interventions
for treatment, control and prevention by different part-
ners, it is prudent to consider introducing more than one
algorithm for use in the country. In the event that one of
the tests is withdrawn from the market, the other algo-
rithm(s) can continue to be used without disrupting serv-
ice provision in various HIV testing programs.
It is apparent that strategies involving the use of Uni-
Gold™ as first or second assay are much more expensive
compared to those which use combinations of the other
assays. The prices for these tests were obtained from the
WHO bulk procurement scheme [15]. Taking into
account the criteria for inclusion into the National algo-
rithm and the element of cost, the possible rapid HIV
serial testing algorithms are: screening by SD Bioline fol-
lowed by confirmatory testing of reactive samples by
Determine with Uni-Gold™ assay as a tiebreaker for dis-
cordant results. The sensitivity and specificity of this strat-
egy is 100%. A strategy based on screening by Determine
followed by confirmatory testing of reactive samples by
SD Bioline with Uni-Gold™ assay as tiebreaker for dis-
cordant results also has a sensitivity of 100% and a specif-
icity of 100%. It would be cheaper to use the former
(involving initial screening with SD Bioline) than the later
algorithm when serial HIV testing is performed because
SD Bioline is relatively cheaper than Determine assay.
However, if testing is done in parallel, the cost would be
similar for both algorithms. An algorithm based on
screening by SD Bioline and confirmatory testing of reac-
tive samples by Stat-Pak Dipstick assay would have a sim-
ilar cost to that of the above named two algorithms but
the initial sensitivity of Stat-Pak Dipstick was 97.7%,
which, according to the protocol did not qualify it for
inclusion into the National algorithm. The cheapest assay
combinations are those involving the use of SD Bioline
and First Response assays, with SD Bioline as the first
assay followed by First Response as the second assay or
vice versa. This algorithm, however, is associated with a
concordant false positive reactivity on the two assays as
well as the fact that First Response had initial sensitivity of
99.5%. It should be noted that the cost of rapid HIV test-
ing algorithm can change to due to changes in prices of
the test kits. A rapid HIV testing strategy that is consistent
with recommendations by WHO [16] is essential for pro-
moting HIV care, treatment and prevention programs.
Results from the current evaluation indicate that a
number of assays have good performance characteristics
suggesting that considering additional operational charac-
teristics other than sensitivity and specificity would be
useful in developing a national rapid HIV testing algo-
rithm for Tanzania. This aspect was taken into account in
the current evaluation during selection of the tests for
inclusion into the evaluation as well as assessment of
additional characteristics.
Conclusion
An alternative confirmatory HIV testing strategy based on
initial testing on either SD Bioline or Determine assays
followed by testing of reactive samples on the Determine
or SD Bioline gave 100% sensitivity (95% CI; 99.1–100)
and 100% specificity (95% CI; 96–99.1) with Uni-Gold™
assay as tie breaker for discordant results.
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